Navigation Links
Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition

Rochester, NY (PRWEB) January 12, 2014

The editors of Science magazine picked cancer immunotherapy as 2013’s major medical breakthrough achievement. Cancer immunotherapy is the use of the immune system to fight cancer. This is done by stimulating the patient's immune system to attack cancer cells. According to an article on, “Scientists have thought for decades that harnessing the immune system to battle tumors should be possible, but it has been incredibly difficult to make it work.” The article was published on January 5, 2014 (2).

“So far, this strategy of harnessing the immune system to attack tumours works only for some cancers and a few patients, so it's important not to overstate the immediate benefits. But many cancer specialists are convinced that they are seeing the birth of an important new paradigm for cancer treatment,” said Tim Appenzeller, chief news editor of Science magazine (1).

Cancer researchers say that they “have turned a corner because two different techniques are helping a subset of patients. One involves antibodies that release a brake on (or stimulate) T cells (a type of white blood cell), giving them the power to tackle tumors. Another involves genetically modifying an individual's T cells outside the body so that they are better able to target cancer, and then re-infusing them so they can do just that. (2).”

Normal cells are programmed to divide and replicate at a certain rate. Cancer cells replicate unchecked, which causes the growth of a tumor. Now, think of the immune system’s T-Cells as guards. They seek out and destroy malfunctioning cells, including cancer cells. In essence, cancer immunotherapy is either adding T-Cells (adding more guards) or teaching them to be more aggressive.

According to the Theory of Microcompetition with Foreign DNA, as detailed by Dr. Hanan Polansky on the CBCD website (3), latent viruses are the cause of most major diseases, including cancer. Latent viruses microcompete for scarce genetic resources in the cells they infect. This causes the cell to “go crazy,” or malfunction.

As long as the immune system is efficient, the T-Cells will find all the malfunctioning cells, and destroy them. Otherwise, some cells will survive and become tumors.

The CBCD sees immunotherapy as an attempt to compensate for a weak immune system. That is, to entice the weak immune system to find malfunctioning cells, specifically those with a high concentration of latent viruses.

However, by eradicating latent viral infections, and therefore avoiding Microcompetition from the start, patients will not develop cancer and will not need cancer therapies.

The Center recommends that health professionals turn to Dr. Polansky’s book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease” for a better understanding of the risks posed by latent viruses, and how helping the immune system to eradicate them may improve cancer patient outcomes.

To learn more about Dr. Hanan Polansky’s research and the Theory of Microcompetition with Foreign DNA, visit:


(1) Science journal’s top 10 breakthroughs, 2013. Published on December 26, 2013.

(2) Science magazine picks top breakthroughs of 2013. Published on January 5, 2014.

(3) CBCD - Foreign DNA Fragments Cause Most Major Diseases.

The CBCD is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Garage Start-ups Now Possible in Life Sciences Industry
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
6. BioSpace Spotlights Northwests Life Science Community
7. CNR Rao wins 2011 Ernesto Illy Trieste Science Prize
8. DiaTech Life Sciences Announces Medical Advisory Board
9. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
10. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
11. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):